Sunday 18 October 2026
Export OBIO’s income statement to Excel — free account
Orchestra BioMed Holdings, Inc.
OBIO Healthcare Biotechnology
Orchestra BioMed Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.5 million, up 1,169.2% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS grew 24.0%, free cash flow fell 25.9% and total debt rose 142.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.45
0.29
−5.05%
Follow OBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
45.93 | 5.92 | 8.15 | 8.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.90) | (87.29) | (12.02) | (14.26) | |
P/B ratio |
2.96 | 3.70 | 6.47 | 14.27 | |
Price to Tangible BV |
2.96 | 3.70 | 6.47 | 14.27 | |
EV/Sales |
16.97 | 3.16 | 5.70 | 6.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.79) | (2.16) | (3.42) | (3.44) | |
EV/FCF |
(0.79) | (2.14) | (3.39) | (3.39) | |
Quick Ratio |
4.64 | 6.37 | 6.90 | 8.17 | |
Current Ratio |
4.73 | 6.45 | 7.03 | 8.26 | |
Net Debt/EBITDA |
4.05 | (13.37) | 3.65 | 3.38 | |
Debt/Assets |
13.55% | 12.42% | 14.24% | 30.11% | |
Debt/Equity |
0.32 | 0.27 | 0.35 | 1.80 | |
Asset Turnover |
0.03 | 0.35 | 0.41 | 0.40 | |
Operating CF/Net income |
0.70 | (0.38) | 1.07 | 0.80 | |
Capex/Depreciation |
(2.21) | (0.23) | (1.19) | (1.58) | |
Research and Development Expense of Revenue |
1,629.15% | 54.41% | 14,346.36% | 18,852.27% | |
Selling, General and Administrative Expense of Revenue |
824.39% | 23.58% | 5,793.64% | 6,623.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
349.94% | 8.89% | 2,591.82% | 2,846.59% | |
Graham Net Nets |
0.28 | 0.24 | 0.14 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(73.39%) | (27.23%) | (22.82%) | (19.68%) | |
Free Cash Flow Yield |
(46.97%) | (24.96%) | (20.66%) | (21.44%) | |
Revenue per Share |
0.02 | 0.65 | 0.00 | 0.00 | |
Operating CF per Share |
(0.28) | (0.05) | (0.35) | (0.30) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.28) | (0.05) | (0.36) | (0.31) | |
Cash per Share |
1.84 | 2.23 | 1.51 | 1.72 | |
Shareholders Equity per Share |
0.84 | 1.12 | 0.66 | 0.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.84 | 1.12 | 0.66 | 0.30 | |
Free Cash Flow |
(14.86) | (2.30) | (22.35) | (19.59) | |
Working Capital |
77.11 | 91.18 | 82.52 | 97.77 | |
Capital Expenditures |
(0.31) | (0.03) | (0.18) | (0.25) | |
Net Current Asset Value |
36.70 | 46.62 | 36.74 | 14.86 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.36 | 0.00 | 1.67 | 2.89 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.08 | 0.09 | 0.09 | 0.07 | |
Average Payables |
6.60 | 5.61 | 5.94 | 5.72 | |
Average Inventory |
0.30 | 0.24 | 0.21 | 0.22 | |
Average Assets |
90.06 | 95.52 | 79.85 | 79.26 | |
Average Common Equity |
44.98 | 43.26 | 29.02 | 9.81 |
Columns are period end dates